Asterias Biotherapeutics Inc(NYSEMKT:AST) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 28, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Earnings per share were $-0.2.
Asterias Biotherapeutics Inc (AST) remained unchanged at the close of Friday session. Even as the volume increased to 76,690 ,the shares failed to make any impression and ended at 0 points or 0.00% at $3.25. The trading session commenced at $3.24 and the stock hit a high of $3.4 and touched $3.2 at the lower end. Considering that the stock pared all of the losses, it can be said as a positive sign. The share price has a 52-week high of $5.8 and the 52-week low is $2.3. The company has a market cap of $151 M and has approximately 4,64,22,452 outstanding shares.
Several Insider Transactions has been reported to the SEC. On Jan 11, 2017, Edward Wirth (Chief Medical Officer) sold 3,415 shares at $4.60 per share price.Also, On Jan 11, 2017, Katharine E. Spink (Chief Operating Officer) sold 4,781 shares at $4.60 per share price.On Jul 1, 2016, Richard T. Lebuhn (director) purchased 5,000 shares at $2.38 per share price, according to the Form-4 filing with the securities and exchange commission.
Asterias Biotherapeutics Inc. is a biotechnology company. The Company is focused in the field of regenerative medicine. It has three clinical stage product candidates: AST-OPC1 indicated for spinal cord injuries; AST-VAC2 indicated for lung cancer and AST-VAC1 indicated for prostate cancer and acute myelogenous leukemia. The Company’s product development is focused primarily on AST-OPC1 and AST-VAC2. The Company’s lead therapeutic program focuses on the development of AST-OPC1 for spinal cord injury. AST-OPC1 product consists of glial progenitor cells which are cells that become glial cells after injection. AST-VAC1 is an autologous product (using cells that come from the treated patient) consisting of mature antigen-presenting dendritic cells pulsed with ribonucleic acid (RNA) for the protein component of human telomerase (hTERT) and a portion of a lysosomal targeting signal (LAMP).